Ethics of Drug Research in the Pediatric Intensive Care Unit

Pediatric Drugs

Volumn 17, Issue 1, 2015, Pages 43-53

  Kleiber, Niina ^a   Tromp, Krista ^b   Mooij, Miriam G ^a   van de Vathorst, Suzanne ^b   Tibboel, Dick ^a   de Wildt, Saskia N ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; ANXIETY; BLOOD ANALYSIS; CHILD; CRITICAL ILLNESS; DISEASE SEVERITY; DOSE CALCULATION; DRIED BLOOD SPOT TESTING; DRUG RESEARCH; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFORMED CONSENT; INTENSIVE CARE UNIT; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; MEDICAL ETHICS; MEDICAL RESEARCH; MICRODOSING METHOD; MODEL; NEWBORN INTENSIVE CARE; NEWBORN SCREENING; OPPORTUNISTIC BLOOD SAMPLING METHOD; OUTCOME ASSESSMENT; PARENTAL ATTITUDE; PHARMACOKINETIC PHARMACODYNAMIC MODEL; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; REVIEW; SPARSE BLOOD SAMPLING METHOD; STUDY DESIGN; VULNERABLE POPULATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ETHICS; RISK FACTOR;

BIOMEDICAL RESEARCH; CHILD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INFORMED CONSENT; INTENSIVE CARE UNITS, PEDIATRIC; RISK FACTORS;

EID: 84921842817     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-014-0101-5     Document Type: Review

References (94)

1. Council for International Organizations of Medical Sciences (CIOMS). International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva 2002.
2. Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10. Washington: US Government Printing Office; 1949. p. 181–2.
3. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington: US Government Printing Office; 1978.
4. Declaration of Helsinki. Ethical principles for medical research involving human subjects (8th revision; original: 1964), 2013.
5. Bos W, Tromp K, Tibboel D, Pinxten W. Ethical aspects of clinical research with minors. Eur J Pediatr. 2013;172(7):859–66. doi:10.1007/s00431-012-1856-8.
6. Shirkey H. Therapeutic orphans. J Pediatr. 1968;72(1):119–20.
7. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Eng J Med. 2003;349(12):1157–67. doi:10.1056/NEJMra035092.
8. Shann F, Chiletti R. Neonatal herpes virus infection: duration of extracorporeal support and the dose of acyclovir. Pediatr Crit Care Med. 2011;12(5):605–6. doi:10.1097/PCC.0b013e3182191780 (author reply).
9. Prodhan P, Okhuysen-Cawley R, Imamura M. Central extracorporeal membrane oxygenation for refractory pediatric septic shock. Pediatr Crit Care Med. 2011;12(5):606–7. doi:10.1097/PCC.0b013e31821917cc (author reply).
10. Conroy S. Association between licence status and medication errors. Arch Dis Child. 2011;96(3):305–6. doi:10.1136/adc.2010.191940.
11. Turner S, Gill A, Nunn T, Hewitt B, Choonara I. Use of “off-label” and unlicensed drugs in paediatric intensive care unit. Lancet. 1996;347(9000):549–50. doi:10.1016/S0140-6736(96)91182-4.
12. Sutherland JM. Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. AMA J Dis Child. 1959;97(6):761–7. doi:10.1001/archpedi.1959.02070010763001.
13. Johnson TN. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology. 2003;192(1):37–48. doi:10.1016/S0300-483X(03)00249-X.
14. Vet NJ, de Hoog M, Tibboel D, de Wildt SN. The effect of inflammation on drug metabolism: a focus on pediatrics. Drug Discov Today. 2011;16(9–10):435–42. doi:10.1016/j.drudis.2011.02.014.
15. Daschner M. Drug dosage in children with reduced renal function. Pediatr Nephrol. 2005;20(12):1675–86. doi:10.1007/s00467-005-1922-9.
16. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–61. doi:10.1007/s00228-008-0553-z.
17. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65(8):757–73. doi:10.1007/s00228-009-0678-8.
18. Wildschut ED, Ahsman MJ, Houmes RJ, Pokorna P, de Wildt SN, Mathot RA, et al. Pharmacotherapy in neonatal and pediatric extracorporeal membrane oxygenation (ECMO). Curr Drug Metab. 2012;13(6):767–77. doi:10.2174/138920012800840383.
19. van den Broek MP, Groenendaal F, Egberts AC, Rademaker CM. Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies. Clin Pharmacokinet. 2010;49(5):277–94. doi:10.2165/11319360-000000000-00000.
20. Schetz M. Drug dosing in continuous renal replacement therapy: general rules. Curr Opin Crit Care. 2007;13(6):645–51. doi:10.1097/MCC.0b013e3282f0a3d3.
21. Best Pharmaceuticals for Children Act, US Public Law 107–109, 2002.
22. European Parliament and the Council of the European Union. Regulation (EC) No. 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No. 726/2004. Off J Eur Union. 2006;49(L 378):1–19.
23. Benjamin DK Jr, Smith PB, Murphy MD, Roberts R, Mathis L, Avant D, et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA. 2006;296(10):1266–73. doi:10.1001/jama.296.10.1266.
24. Wimmer S, Rascher W, McCarthy S, Neubert A. The eu paediatric regulation: still a large discrepancy between therapeutic needs and approved paediatric investigation plans. Paediatr Drugs. 2014. doi:10.1007/s40272-014-0082-4.
25. Davies EH, Ollivier CM, Saint Raymond A. Paediatric investigation plans for pain: painfully slow! Eur J Clin Pharmacol. 2010;66(11):1091–7. doi:10.1007/s00228-010-0886-2.
26. Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin Pharmacol Ther. 2012;91(5):796–801. doi:10.1038/clpt.2012.26.
27. Yang CP, Veltri MA, Anton B, Yaster M, Berkowitz ID. Food and Drug Administration approval for medications used in the pediatric intensive care unit: a continuing conundrum. Pediatr Crit Care Med. 2011;12(5):e195–9. doi:10.1097/PCC.0b013e3181fe25b9.
28. Doherty DR, Pascuet E, Ni A, Stewart P, Splinter W, Vaillancourt R. Off-label drug use in pediatric anesthesia and intensive care according to official and pediatric reference formularies. Can J Anaesth. 2010;57(12):1078–88. doi:10.1007/s12630-010-9395-0.
29. Ceelie I, van der Starre C, Tibboel D, Stol K, Koren G, de Wildt SN. Evaluation of drug formularies for pediatric intensive care. Pediatr Crit Care Med. 2011;12(1):e14–9. doi:10.1097/PCC.0b013e3181d90228.
30. Morris AD, Zaritsky AL, LeFever G. Evaluation of ethical conflicts associated with randomized, controlled trials in critically ill children. Crit Care Med. 2000;28(4):1152–6. doi:10.1097/00003246-199801001-00173.
31. Duffett M, Choong K, Hartling L, Menon K, Thabane L, Cook DJ. Randomized controlled trials in pediatric critical care: a scoping review. Crit Care. 2013;17(5):R256. doi:10.1186/cc13083.
32. Sharkey K, Savulescu J, Aranda S, Schofield P. Clinician gate-keeping in clinical research is not ethically defensible: an analysis. J Med Ethics. 2010;36(6):363–6. doi:10.1136/jme.2009.031716.
33. Menon K, Ward R, Canadian Critical Care Trials Group. A study of consent for participation in a non-therapeutic study in the pediatric intensive care population. J Med Ethics. 2014;40(2):123–6. doi:10.1136/medethics-2012-101075.
34. Harron K, Lee T, Ball T, Mok Q, Gamble C, Macrae D, et al. Making co-enrolment feasible for randomised controlled trials in paediatric intensive care. PloS One. 2012;7(8):e41791. doi:10.1371/journal.pone.0041791.
35. Duffett M, Choong K, Foster J, Cheng J, Meade MO, Menon K, et al. Clonidine in the sedation of mechanically ventilated children: a pilot randomized trial. J Crit Care. 2014;29(5):758–63. doi:10.1016/j.jcrc.2014.05.029.
36. Rabe H. The need for noninvasive biomarkers for drug safety in neonatal circulation. Biomarkers Med. 2010;4(5):771–6. doi:10.2217/bmm.10.88.
37. Vet NJ, Ista E, de Wildt SN, van Dijk M, Tibboel D, de Hoog M. Optimal sedation in pediatric intensive care patients: a systematic review. Intensive Care Med. 2013;39(9):1524–34. doi:10.1007/s00134-013-2971-3.
38. de Graaf J, van Lingen RA, Valkenburg AJ, Weisglas-Kuperus N, Groot Jebbink L, Wijnberg-Williams B, et al. Does neonatal morphine use affect neuropsychological outcomes at 8 to 9 years of age? Pain. 2013;154(3):449–58. doi:10.1016/j.pain.2012.12.006.
39. Holubkov R, Dean JM, Berger J, Anand KJ, Carcillo J, Meert K, et al. Is “rescue” therapy ethical in randomized controlled trials? Pediatr Crit Care Med. 2009;10(4):431–8. doi:10.1097/PCC.0b013e318198bd13.
40. European Parliament and the Council of the Europan Union. Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Off J Eur Union. 2014;57(L 158):1–76.
41. Protections for children involved as subjects in research (45 CFR Part 46, Subpart D), 2009.
42. Kent G. Shared understandings for informed consent: the relevance of psychological research on the provision of information. Soc Sci Med. 1996;43(10):1517–23. doi:10.1016/0277-9536(96)00173-6.
43. Cuttini M. Proxy informed consent in pediatric research: a review. Early Hum Dev. 2000;60(2):89–100. doi:10.1016/S0378-3782(00)00106-7.
44. Balluffi A, Kassam-Adams N, Kazak A, Tucker M, Dominguez T, Helfaer M. Traumatic stress in parents of children admitted to the pediatric intensive care unit. Pediatr Crit Care Med. 2004;5(6):547–53. doi:10.1097/01.PCC.0000137354.19807.44.
45. Rees G, Gledhill J, Garralda ME, Nadel S. Psychiatric outcome following paediatric intensive care unit (PICU) admission: a cohort study. Intensive Care Med. 2004;30(8):1607–14. doi:10.1007/s00134-004-2310-9.
46. Woolfall K, Frith L, Gamble C, Young B. How experience makes a difference: practitioners’ views on the use of deferred consent in paediatric and neonatal emergency care trials. BMC Med Ethics. 2013;14:45. doi:10.1186/1472-6939-14-45.
47. Menon K, Ward RE, Gaboury I, Thomas M, Joffe A, Burns K, et al. Factors affecting consent in pediatric critical care research. Intensive Care Med. 2012;38(1):153–9. doi:10.1007/s00134-011-2412-0.
48. Thomas M, Menon K. Consenting to pediatric critical care research: understanding the perspective of parents. Dynamics. 2013;24(3):18–24.
49. Hulst JM, Peters JW, van den Bos A, Joosten KF, van Goudoever JB, Zimmermann LJ, et al. Illness severity and parental permission for clinical research in a pediatric ICU population. Intensive Care Med. 2005;31(6):880–4. doi:10.1007/s00134-005-2647-8.
50. Flanagan BM, Philpott S, Strosberg MA. Protecting participants of clinical trials conducted in the intensive care unit. J Intensive Care Med. 2011;26(4):237–49. doi:10.1177/0885066610390867.
51. Needle JS, O’Riordan M, Smith PG. Parental anxiety and medical comprehension within 24 hrs of a child’s admission to the pediatric intensive care unit*. Pediatr Crit Care Med. 2009;10(6):668–74. doi:10.1097/PCC.0b013e3181a706c9 (quiz 74).
52. Ballard HO, Shook LA, Desai NS, Anand KJ. Neonatal research and the validity of informed consent obtained in the perinatal period. J Perinatol. 2004;24(7):409–15. doi:10.1038/sj.jp.7211142.
53. Mason SA, Allmark PJ. Obtaining informed consent to neonatal randomised controlled trials: interviews with parents and clinicians in the Euricon study. Lancet. 2000;356(9247):2045–51. doi:10.1016/S0140-6736(00)03401-2.
54. Chappuy H, Baruchel A, Leverger G, Oudot C, Brethon B, Haouy S, et al. Parental comprehension and satisfaction in informed consent in paediatric clinical trials: a prospective study on childhood leukaemia. Arch Dis Child. 2010;95(10):800–4. doi:10.1136/adc.2009.180695.
55. Tait AR, Voepel-Lewis T, Malviya S. Do they understand? (part I): parental consent for children participating in clinical anesthesia and surgery research. Anesthesiology. 2003;98(3):603–8. doi:10.1097/00000542-200303000-00005.
56. Raymond TT, Carroll TG, Sales G, Morris MC. Effectiveness of the informed consent process for a pediatric resuscitation trial. Pediatrics. 2010;125(4):e866–75. doi:10.1542/peds.2009-2427.
57. US Department of Health and Human Services. Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors: Exception from Informed Consent Requirements for Emergency Research (updated 2013). March 2011.
58. Koogler T. Legal and ethical policies regarding research involving critically ill children. Virtual Mentor. 2012;14(10):797–800. doi:10.1001/virtualmentor.2012.14.10.pfor1-1210.
59. Gamble C, Nadel S, Snape D, McKay A, Hickey H, Williamson P, et al. What parents of children who have received emergency care think about deferring consent in randomised trials of emergency treatments: postal survey. PloS One. 2012;7(5):e35982. doi:10.1371/journal.pone.0035982.
60. Woolfall K, Young B, Frith L, Appleton R, Iyer A, Messahel S, et al. Doing challenging research studies in a patient-centred way: a qualitative study to inform a randomised controlled trial in the paediatric emergency care setting. BMJ Open. 2014;4(5):e005045. doi:10.1136/bmjopen-2014-005045.
61. Eltorki M, Uleryk E, Freedman SB. Waiver of informed consent in pediatric resuscitation research: a systematic review. Acad Emerg Med. 2013;20(8):822–34. doi:10.1111/acem.12180.
62. Duffett M, Burns KE, Kho ME, Lauzier F, Meade MO, Arnold DM, et al. Consent in critical care trials: a survey of Canadian research ethics boards and critical care researchers. J Crit Care. 2011;26(5):533 e11–22. doi:10.1016/j.jcrc.2010.12.009.
63. Jansen TC, Bakker J, Kompanje EJ. Inability to obtain deferred consent due to early death in emergency research: effect on validity of clinical trial results. Intensive Care Med. 2010;36(11):1962–5. doi:10.1007/s00134-010-1988-0.
64. Jansen TC, Kompanje EJ, Druml C, Menon DK, Wiedermann CJ, Bakker J. Deferred consent in emergency intensive care research: what if the patient dies early? Use the data or not? Intensive Care Med. 2007;33(5):894–900. doi:10.1007/s00134-007-0580-8.
65. Maitland K, Molyneux S, Boga M, Kiguli S, Lang T. Use of deferred consent for severely ill children in a multi-centre phase III trial. Trials. 2011;12:90. doi:10.1186/1745-6215-12-90.
66. Simons SH, van Dijk M, van Lingen RA, Roofthooft D, Duivenvoorden HJ, Jongeneel N, et al. Routine morphine infusion in preterm newborns who received ventilatory support: a randomized controlled trial. JAMA. 2003;290(18):2419–27. doi:10.1001/jama.290.18.2419.
67. van Dijk M, Bouwmeester NJ, Duivenvoorden HJ, Koot HM, Tibboel D, Passchier J, et al. Efficacy of continuous versus intermittent morphine administration after major surgery in 0–3-year-old infants; a double-blind randomized controlled trial. Pain. 2002;98(3):305–13. doi:10.1016/S0304-3959(02)00031-3.
68. Knibbe CA, Krekels EH, van den Anker JN, DeJongh J, Santen GW, van Dijk M, et al. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet. 2009;48(6):371–85. doi:10.2165/00003088-200948060-00003.
69. Krekels EH, Tibboel D, de Wildt SN, Ceelie I, Dahan A, van Dijk M, et al. Evidence-based morphine dosing for postoperative neonates and infants. Clin Pharmacokinet. 2014. doi:10.1007/s40262-014-0135-4.
70. Ahsman MJ, Tibboel D, Mathot RA, de Wildt SN. Sample collection, biobanking, and analysis. Handb Exp Pharmacol. 2011;205:203–17. doi:10.1007/978-3-642-20195-0_10.
71. Autmizguine J, Benjamin DK, Smith PB, Sampson M, Ovetchkine P, Cohen-Wolkowiez M, et al. Pharmacokinetic studies in infants using minimal-risk study designs. Curr Clin Pharmacol. 2014.
72. Howie SR. Blood sample volumes in child health research: review of safe limits. Bull World Health Organ. 2011;89(1):46–53. doi:10.2471/BLT.10.080010.
73. Vogeser M, Seger C. A decade of HPLC-MS/MS in the routine clinical laboratory—goals for further developments. Clin Biochem. 2008;41(9):649–62. doi:10.1016/j.clinbiochem.2008.02.017.
74. Jebrail MJ, Bartsch MS, Patel KD. Digital microfluidics: a versatile tool for applications in chemistry, biology and medicine. Lab Chip. 2012;12(14):2452–63. doi:10.1039/c2lc40318h.
75. Wootton RC, Demello AJ. Microfluidics: analog-to-digital drug screening. Nature. 2012;483(7387):43–4. doi:10.1038/483043a.
76. Lafreniere NM, Shih SC, Abu-Rabie P, Jebrail MJ, Spooner N, Wheeler AR. Multiplexed extraction and quantitative analysis of pharmaceuticals from DBS samples using digital microfluidics. Bioanalysis. 2014;6(3):307–18. doi:10.4155/bio.13.311.
77. Li CG, Lee CY, Lee K, Jung H. An optimized hollow microneedle for minimally invasive blood extraction. Biomed Microdevices. 2013;15(1):17–25. doi:10.1007/s10544-012-9683-2.
78. Lehmann S, Delaby C, Vialaret J, Ducos J, Hirtz C. Current and future use of “dried blood spot” analyses in clinical chemistry. Clin Chem Lab Med. 2013;51(10):1897–909. doi:10.1515/cclm-2013-0228.
79. Cohen-Wolkowiez M, Watt KM, Zhou C, Bloom BT, Poindexter B, Castro L, et al. Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants. Antimicrob Agents Chemother. 2014;58(5):2856–65. doi:10.1128/AAC.02139-13.
80. Spooner N, Lad R, Barfield M. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. Anal Chem. 2009;81(4):1557–63. doi:10.1021/ac8022839.
81. de Boer T, Wieling J, Meulman E, Reuvers M, Renkema G, den Daas I, et al. Application of dried blood spot sampling combined with LC–MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers. Biomed Chromatogr BMC. 2011;25(10):1112–23. doi:10.1002/bmc.1580.
82. Hollegaard MV, Grauholm J, Nielsen R, Grove J, Mandrup S, Hougaard DM. Archived neonatal dried blood spot samples can be used for accurate whole genome and exome-targeted next-generation sequencing. Mol Genet Metab. 2013;110(1–2):65–72. doi:10.1016/j.ymgme.2013.06.004.
83. Hollegaard MV, Grauholm J, Norgaard-Pedersen B, Hougaard DM. DNA methylome profiling using neonatal dried blood spot samples: a proof-of-principle study. Mol Genet Metab. 2013;108(4):225–31. doi:10.1016/j.ymgme.2013.01.016.
84. Admiraal R, van Kesteren C, Boelens JJ, Bredius RG, Tibboel D, Knibbe CA. Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. Arch Dis Child. 2014;99(3):267–72. doi:10.1136/archdischild-2013-303721.
85. Marsot A, Boulamery A, Bruguerolle B, Simon N. Population pharmacokinetic analysis during the first 2 years of life: an overview. Clin Pharmacokinet. 2012;51(12):787–98. doi:10.1007/s40262-012-0015-8.
86. De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA. The role of population PK–PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2011;67(Suppl. 1):5–16. doi:10.1007/s00228-009-0782-9.
87. Ahsman MJ, Wildschut ED, Tibboel D, Mathot RA. Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 2010;54(5):1734–41. doi:10.1128/AAC.01696-09.
88. Vuong LT, Blood AB, Vogel JS, Anderson ME, Goldstein B. Applications of accelerator MS in pediatric drug evaluation. Bioanalysis. 2012;4(15):1871–82. doi:10.4155/bio.12.173.
89. European Medicines Agency. ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. 2009.
90. US Department of Health and Human Services. Guidance for industry, investigators and reviewers: exploratory IND studies. 2006.
91. Salehpour M, Possnert G, Bryhni H. Subattomole sensitivity in biological accelerator mass spectrometry. Anal Chem. 2008;80(10):3515–21. doi:10.1021/ac800174j.
92. Vet NJ, de Wildt SN, Verlaat CW, Knibbe CA, Mooij MG, Hop WC, et al. Daily interruption of sedation in critically ill children: study protocol for a randomized controlled trial. Trials. 2014;15:55. doi:10.1186/1745-6215-15-55.
93. Carroll TG, Dimas VV, Raymond TT. Vasopressin rescue for in-pediatric intensive care unit cardiopulmonary arrest refractory to initial epinephrine dosing: a prospective feasibility pilot trial. Pediatr Crit Care Med. 2012;13(3):265–72. doi:10.1097/PCC.0b013e31822f1569.
94. Mooij MG, van Duijn E, Knibbe CA, Windhorst AD, Hendrikse NH, Vaes WH, et al. Pediatric microdose study of [C]Paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept. Clin Pharmacokinet. 2014. doi:10.1007/s40262-014-0176-8.